<Disease><Name>GAUCHER DISEASE TYPE III</Name><Synonym>GAUCHER DISEASE, SUBACUTE NEURONOPATHIC TYPE</Synonym><OMIM><Number>231000</Number><URL>http://omim.org/entry/231000</URL></OMIM><Orphanet><Number>77261</Number><URL>http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=EN&amp;Expert=77261</URL></Orphanet><Protein><Number>Glucosylceramidase</Number><URL>http://www.uniprot.org/uniprot/P04062</URL></Protein><ExPASy><Number>3.2.1.45</Number><URL>http://enzyme.expasy.org/EC/3.2.1.45</URL></ExPASy><Gene>1q22</Gene><ICD>E75.2</ICD><Summary>Rare (&gt;350 patients) ;autosomal recessive ;type I is mainly found in Ashkenazic Jews ;3 types: ;- chronic/adult (I) MIM 230800 ;- acute/infantile(II) MIM 230900 ;- juvenile (III) MIM 231000;- cardiovascular (IIIC) MIM 231005</Summary><Symptoms><symtomp><id>1942</id><symptom>ataxia</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>1955</id><symptom>behavior, hyperactive, restless / behaviour, hyperactive, restless</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>2028</id><symptom>bone marrow abnormality</symptom><category>IMMUNE OR HEMATOLOGIC SYSTEM</category></symtomp><symtomp><id>3158</id><symptom>cardiac involvement, defects or anomalies</symptom><category>CARDIOVASCULAR SYSTEM</category></symtomp><symtomp><id>3165</id><symptom>dementia</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>2564</id><symptom>DNA / deoxyribonucleic acid</symptom><category>LABORATORY FINDINGS</category></symtomp><symtomp><id>1969</id><symptom>extrapyramidal signs</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>1724</id><symptom>eye movements, abnormal</symptom><category>EYES</category></symtomp><symtomp><id>1994</id><symptom>hepatomegaly (large liver)</symptom><category>GASTROINTESTINAL SYSTEM</category></symtomp><symtomp><id>1715</id><symptom>infections (severe or recurrent)</symptom><category>GENERAL TOPICS | IMMUNE OR HEMATOLOGIC SYSTEM</category></symtomp><symtomp><id>2424</id><symptom>mental retardation</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>1941</id><symptom>motor retardation / motor developmental delay</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>1900</id><symptom>myoclonus</symptom><category>MUSCLES | NERVOUS SYSTEM</category></symtomp><symtomp><id>1917</id><symptom>neurological deterioration / neurologic deterioration</symptom><category>GENERAL TOPICS | NERVOUS SYSTEM</category></symtomp><symtomp><id>3369</id><symptom>neuropathy</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>2507</id><symptom>onset, childhood / childhood</symptom><category>GENERAL TOPICS</category></symtomp><symtomp><id>1943</id><symptom>seizures</symptom><category>NERVOUS SYSTEM | NERVOUS SYSTEM</category></symtomp><symtomp><id>2109</id><symptom>short stature</symptom><category>GENERAL TOPICS</category></symtomp><symtomp><id>1974</id><symptom>spastic diplegia/quadriplegia/tetraplegia</symptom><category>NERVOUS SYSTEM | NERVOUS SYSTEM</category></symtomp><symtomp><id>1874</id><symptom>speech development, delayed, abnormal</symptom><category>GENERAL TOPICS | NERVOUS SYSTEM</category></symtomp><symtomp><id>2042</id><symptom>splenomegaly (large spleen)</symptom><category>GASTROINTESTINAL SYSTEM</category></symtomp><symtomp><id>3199</id><symptom>thrombopenia, thrombocytopenia</symptom><category>LABORATORY FINDINGS</category></symtomp></Symptoms><Metabolites><metabolite><id>969</id><name>Glucocerebrosidase</name><specimen>fibroblasts</specimen><value>decreased</value><min>    </min><max>100.00</max><unit>% activity</unit><age>no data</age><method /><comment /></metabolite><metabolite><id>970</id><name>Glucocerebrosidase</name><specimen>leucocytes</specimen><value>decreased</value><min>    </min><max>100.00</max><unit>% activity</unit><age>no data</age><method /><comment /></metabolite></Metabolites><Literatures><literature><id>7919</id><title>The definition of neuronopathic Gaucher disease</title><author>Schiffmann R,</author><journal>J Inherit Metab Dis</journal><year>2020</year><book /><volume>0</volume><number>0</number><pages /><co_aut>et al.</co_aut></literature><literature><id>6976</id><title>Gaucher disease type 3c: New patients with unique presentations and review of the literature</title><author>Kurolap A,</author><journal>Mol Genet Metab</journal><year>2019</year><book /><volume>127</volume><number>2</number><pages>138-146</pages><co_aut>et al.</co_aut></literature><literature><id>4121</id><title>A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments</title><author>Stirnemann J,</author><journal>Int J Mol Sci</journal><year>2017</year><book /><volume>18</volume><number>2</number><pages /><co_aut>et al.</co_aut></literature><literature><id>4534</id><title>Severe cardiac involvement in Gaucher type IIIC: a case report and review of the literature</title><author>Koer Y,</author><journal>Cardiol Young</journal><year>2017</year><book /><volume>27</volume><number>7</number><pages>1426-1429</pages><co_aut>Keskin M, Ba&#351;p&#305;nar O</co_aut></literature><literature><id>4536</id><title>Gaucher disease epidemiology and natural history: a comprehensive review of the literature</title><author>Nalysnyk L,</author><journal>Hematology. 2017 Mar;22(2):65-73.</journal><year>2017</year><book /><volume>22</volume><number>2</number><pages>65-73</pages><co_aut>et al.</co_aut></literature><literature><id>4538</id><title>Gaucher disease: Progress and ongoing challenges</title><author>Mistry PK,</author><journal>Mol Genet Metab</journal><year>2017</year><book /><volume>120</volume><number>1</number><pages>8-21</pages><co_aut>et al.</co_aut></literature><literature><id>6045</id><title>Characteristics of 26 patients with type 3 Gaucher disease: A descriptive analysis from the Gaucher Outcome Survey</title><author>Schwartz IVD,</author><journal>Mol Genet Metab Rep</journal><year>2017</year><book /><volume>14</volume><number>0</number><pages>73-79</pages><co_aut>et al.</co_aut></literature><literature><id>4539</id><title>New Directions in Gaucher Disease</title><author>Horowitz M,</author><journal>Hum Mutat</journal><year>2016</year><book /><volume>37</volume><number>11</number><pages>1121-1136</pages><co_aut>et al.</co_aut></literature><literature><id>2495</id><title>Myoclonic epilepsy in Gaucher disease: genotype-phenotype insights from a rare patient subgroup</title><author>Park JK</author><journal>Pediatr Res</journal><year>2002</year><book /><volume>53</volume><number>3</number><pages>387-395</pages><co_aut>et al.</co_aut></literature><literature><id>2643</id><title>Communicating hydrocephalus in a patient with Gauchers disease type 3</title><author>Shiihara T</author><journal>Pediatr Neurol</journal><year>2000</year><book /><volume>22</volume><number>3</number><pages>234-236</pages><co_aut>et al.</co_aut></literature><literature><id>868</id><title>The effect of enzyme therapy in a  patient with Gaucher disease type III</title><author>Bosman DK</author><journal>J Inherit Metab Dis</journal><year>1996</year><book /><volume>19</volume><number>0</number><pages>703-704</pages><co_aut>et al.</co_aut></literature><literature><id>161</id><title>Gaucher disease</title><author>Beutler E</author><journal>The metabolic and molecular bases of inherited disease, 7/e; Editors: C.R.Scriver, A.L.Beaudet, W.S.Sly, D.Valle; McGraw-Hill Inc.</journal><year>1995</year><book /><volume>2</volume><number>86</number><pages>2641-2670</pages><co_aut>Grabowski GA</co_aut></literature><literature><id>865</id><title>Enzyme infusion therapy of the Norrbottnian (type 3) Gaucher disease</title><author>Erikson A</author><journal>Neuropediatrics</journal><year>1995</year><book /><volume>26</volume><number>0</number><pages>203-207</pages><co_aut>et al.</co_aut></literature></Literatures></Disease>